ArticleEuropean journal of nuclear medicine and molecular imaging2019
Article in European journal of nuclear medicine and molecular imaging, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- The [European journal of nuclear medicine and molecular imaging · 2026Pooled it
- Prognostic value ofClinical and experimental medicine · 2023Pooled it
- Prognostic value ofEuropean radiology · 2021Pooled it
- Chemokine receptor-4 targeted PET/CT withEuropean journal of nuclear medicine and molecular imaging · 2020Trial
- Fifteen years of use of functional imaging in multiple myeloma: where we started and where we are going.Blood advances · 2025Review
- Evidence-based Korean guidelines for the clinical management of multiple myeloma: addressing 12 key clinical questions.Blood research · 2025Review
- Coefficient of variation and texture analysis of 18F-FDG PET/CT images for the prediction of outcome in patients with multiple myeloma.Annals of hematology · 2024Article
- [European journal of nuclear medicine and molecular imaging · 2024Article
- Hybrid simultaneous whole-body 2-[European radiology · 2023Article
- Head-to-Head Comparison of FDG and Radiolabeled FAPI PET: A Systematic Review of the Literature.Life (Basel, Switzerland) · 2023Review
- Cluster analysis of autoencoder-extracted FDG PET/CT features identifies multiple myeloma patients with poor prognosis.Scientific reports · 2023Article
- Prognostic value of semi-quantitative parameters ofAnnals of nuclear medicine · 2023Article
- Comprehensive analysis of ferroptosis-related genes in immune infiltration and prognosis in multiple myeloma.Frontiers in pharmacology · 2023Article
- Article
- Progress of modern imaging modalities in multiple myeloma.International journal of hematology · 2022Review
- 18F-FDG-PET/CT in relapsed multiple myeloma: Are prognostic thresholds different from first-line therapy?BMC medical imaging · 2022Article
- Comparison of [68Ga]-FAPI PET/CT and [18F]-FDG PET/CT in Multiple Myeloma: Clinical Experience.Tomography (Ann Arbor, Mich.) · 2022Article
- Pretreatment Serum Levels of IL-1 Receptor Antagonist and IL-4 Are Predictors of Overall Survival in Multiple Myeloma Patients Treated with Bortezomib.Journal of clinical medicine · 2021Article
- A prognostic survival model based on metabolism-related gene expression in plasma cell myeloma.Leukemia · 2021Article
- Prognostic impact ofInternational journal of hematology · 2021Article
Corrections and comments
- Commented on by
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study evaluated the prognostic role of
methodWe retrospectively analyzed the records of 167 patients with newly diagnosed MM.
resultsIn the total cohort, the presence of more than three hypermetabolic focal lesions (FLs) or extramedullary disease (EMD) on baseline PET/CT was associated with significantly inferior progression-free survival (PFS) and overall survival (OS) than other patients. Because most patients (91%) with EMD had more than three FLs, PET/CT positivity was defined as the presence of more than three FLs or the presence of EMD. In multivariate analyses, PET/CT positivity was an independent predictor of PFS and OS in all patients. Fifty-five patients (46.1%) with R-ISS II were PET/CT-positive at baseline and had significantly shorter PFS and OS. PET/CT positivity was also correlated with poor PFS and OS in patients with R-ISS III.
conclusion
Indexed as
Identifiers
30187105What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.